Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine

Investigative Radiology

Volumn 42, Issue 8, 2007, Pages 579-585

  Albrecht, Thomas ^a   Speck, Ulrich ^a   Baier, Claudia ^a   Wolf, Karl Jürgen ^a   Böhm, Michael ^b   Scheller, Bruno ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Intimal hyperplasia; Local drug delivery; Percutaneous transluminal angioplasy; Peripheral arteries; Restenosis

Indexed keywords

IOPROMIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOGRAPHY; ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STENT; SWINE;

EID: 34447344859     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31804f5a60     Document Type: Article

References (47)

1. Gupta AK, Ravimandalam K, Rao VR, et al. Total occlusion of iliac arteries: results of balloon angioplasty. Cardiovasc Intervent Radiol. 1993;16:165-177.
2. Jorgensen B, Skovgaard N, Norgard J, et al. Percutaneous transluminal angioplasty in 226 iliac artery stenoses: role of the superficial femoral artery for clinical success. Vasa. 1992;21:382-386.
3. Johnston KW. Iliac arteries: reanalysis of results of balloon angioplasty. Radiology. 1993;186:207-212.
4. Stokes KR, Strunk HM, Campbell DR, et al. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology. 1990;174:977-982.
5. Tegtmeyer CJ, Hartwell GD, Selby JB, et al. Results and complications of angioplasty in aortoiliac disease. Circulation. 1991;83:I53-I60.
6. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31.
7. Karch LA, Mattos MA, Henretta JP, et al. Clinical failure after percutaneous transluminal angioplasty of the superficial femoral and popliteal arteries. J Vasc Surg. 2000;31:880-887.
8. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology. 1994;191:727-733.
9. Soder HK, Manninen HI, Rasanen HT, et al. Failure of prolonged dilation to improve long-term patency of femoropopliteal artery angioplasty: results of a prospective trial. J Vasc Interv Radiol. 2002;13:361-369.
10. Grenacher L, Saam T, Geier A, et al. PTA versus Palmaz stent placement in femoropopliteal artery stenoses: results of a multicenter prospective randomized study (REFSA). Rofo. 2004;176:1302-1310.
11. Vorwerk D, Gunther RW, Schurmann K, et al. Aortic and iliac stenoses: follow-up results of stent placement after insufficient balloon angioplasty in 118 cases. Radiology. 1996;198:45-48.
12. Vorwerk D, Guenther RW, Schurmann K, et al. Primary stent placement for chronic iliac artery occlusions: follow-up results in 103 patients. Radiology. 1995;194:745-749.
13. Sullivan TM, Childs MB, Bacharach JM, et al. Percutaneous transluminal angioplasty and primary stenting of the iliac arteries in 288 patients. J Vasc Surg. 1997;25:829-838; discussion 838-839.
14. Schurmann K, Mahnken A, Meyer J, et al. Long-term results 10 years after iliac arterial stent placement. Radiology. 2002;224:731-738.
15. Lammer J, Dake MD, Bleyn J, et al. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology. 2000;217:95-104.
16. Murphy TP, Ariaratnam NS, Carney WI Jr, et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology. 2004;231:243-249.
17. Henry M, Amor M, Ethevenot G, et al. Palmaz stent placement in iliac and femoropopliteal arteries: primary and secondary patency in 310 patients with 2-4-year follow-up. Radiology. 1995;197:167-174.
18. Strecker EP, Boos IB, Gottmann D. Femoropopliteal artery stent placement: evaluation of long-term success. Radiology. 1997;205:375-383.
19. White GH, Liew SC, Waugh RC, et al. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation. J Vasc Surg. 1995;21:270-279; discussion 279-281.
20. Gray BH, Sullivan TM, Childs MB, et al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg. 1997;25:74-83.
21. Guzman LA, Mick MJ, Arnold AM, et al. Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Arterioscler Thromb Vasc Biol. 1996;16:479-487.
22. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation. 1994;89:2816-2821.
23. Moses JW, Kipshidze N, Leon MB. Perspectives of drug-eluting stents: the next revolution. Am J Cardiovasc Drugs. 2002;2:163-172.
24. Isner JM. Vascular remodeling. Honey, I think I shrunk the artery. Circulation. 1994;89:2937-2941.
25. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation. 1994;90:2070-2084.
26. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000;102:2694-2699.
27. Waksman R, Laird JR, Jurkovitz CT, et al. Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. J Vasc Interv Radiol. 2001;12:915-921.
28. Krueger K, Landwehr P, Bendel M, et al. Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology. 2002;224:519-528.
29. Wohlgemuth WA, Bohndorf K. Endovascular brachytherapy to prevent restenosis after angioplasty. Rofo. 2003;175:246-252.
30. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
31. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
32. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338.
33. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106:1505-1509.
34. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24:1462-1467.
35. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-1420.
36. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-814.
37. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124.
38. Schwartz RS, Edelman ER, Carter A, et al. Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation. 2004;110:2498-2505.
39. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89:133-138.
40. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004-1014.
41. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-2295.
42. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
43. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-479.
44. Satzl S, Henn C, Christoph P, et al. The efficacy of nanoscale poly[bis(trifluoroethoxy)phosphazene] (PTFEP) coatings in reducing thrombogenicity and late in-stent stenosis in a porcine coronary artery model. Invest Radiol. 2007;42:303-311.
45. Gershlick AH. Treating atherosclerosis: local drug delivery from laboratory studies to clinical trials. Atherosclerosis. 2002;160:259-271.
46. Speck U, Scheller B, Abramjuk C, et al. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol. 2004;39:182-186.
47. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-1385.